Adding ONTY to my watchlist.
Oncothyreon Inc. (ONTY) announces Phase 3 Trial
June 22, 2009 · Filed Under General · Comments Off
Oncothyreon Inc. has announced that Merck KGaA of Darmstadt, Germany, has initiated a global 3 trial of Stimuvax. Stimuvax is an investigational therapeutic cancer vaccine being developed by Merck KGaA under a license agreement with Oncothyreon.
The trial will be conducted in patients with hormone receptor-positive, locally advanced, recurrent or metastatic breast cancer.
Oncothyreon opened Monday up 0.38 (16.67%) with a trade price of 2.66.
The phase 3 trial, named STRIDE (Stimulating immune response in advanced breast cancer), is anticipated to enroll more than 900 patients at approximately 180 sites in over 30 countries - including North America, Europe, Asia and Australia. The primary endpoint of STRIDE is progression-free survival. Overall survival, quality of life, tumor response and safety will also be assessed in this study.
Advanced-stage breast cancer remains a devastating and challenging disease and we urgently need new treatment options," said Dr. Larry Shulman, Chief Medical Officer and Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, Massachusetts, and Principal Investigator of STRIDE. "If the results from the Phase 3 STRIDE study prove positive, this could make a difference for patients with hormone receptor positive metastatic breast cancer."
Joshua Sherman
News 
Market Data 
Discover 
